Alpine Immune Sciences
AcquiredAlpine Immune Sciences develops treatments for inflammatory diseases and cancer.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2015
- Type
- Corporation Seattle business license
- Employees
- 51–200
- Status
- Acquired
- Registered name
- Ais Operating Co Inc Seattle business license
- Stage
- Acquired
- Members see funding amounts. .
Is this your organization? Claim it
Ally.io raises $50M Series C, bringing total funding to $76M; investors include Accel, Addition, GreenOaks
Ally.io, a Seattle-based company led by co-founder & CEO Vetri Vellore, has raised $76M total with a $50M Series C as its most recent round in February 2021, backed by investors including Accel, Addition, and GreenOaks.
InduPro names Prakash Raman, Ph.D. CEO; Amanda J. Redig, M.D., Ph.D. serves as CMO with deep biopharma backgrounds
This page profiles InduPro's leadership, highlighting CEO Prakash Raman, Ph.D., and CMO Amanda J. Redig, M.D., Ph.D., summarizing their education and extensive biopharma and drug development experience. It emphasizes Raman’s prior roles at Ribon Therapeutics, Flagship Pioneering, and Novartis and his track record in business development, collaborations, and advancing drug candidates to clinical testing.
Frazier Healthcare Partners closes $1.3 billion early‑stage biotech fund after leading many 2024 deals and scoring big exits
Frazier Healthcare Partners has closed a $1.3 billion venture fund to back early-stage biotech startups, building on a busy 2024 where it led nearly a third of 17 deals and scored major exits like Scorpion Therapeutics’ $2.5 billion drug sale to Eli Lilly. The fund follows other recent life‑sciences raises and arrives as overall biotech VC funding has declined.
See all 12 news stories about Alpine Immune Sciences.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events